Form 4: Director Michael Houghton Receives Stock Option Grant

Assembly Biosciences director Michael Houghton was granted 8,000 stock options as part of standard equity compensation.

Summary

• Director Michael Houghton was granted 8,000 stock options to purchase common stock in Assembly Biosciences, Inc.
• The options have an exercise price of $24.11 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $24.11 exercise price.

Future Outlook

The options vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders, contingent upon continuous service.

Management Comments

• The transaction represents a standard equity grant for a director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical non-employee director compensation packages for small-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 4, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Assembly Biosciences, ASMB, Form 4, Insider Trading, Stock Options, Director Compensation